公开(公告)号：US20250043024A1

公开(公告)日：2025-02-06

申请号：US18772484

申请日：2024-07-15

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alfred Engel ,  Frank Kroner ,  Thomas Meier ,  Sandra Rutz ,  Michael Schraeml ,  Gloria Tabares ,  Ulrike Kurtkaya ,  Boris Pinchuk ,  Christina Zimmermann

IPC: C07K16/40 ,  G01N33/543

Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1

公开(公告)号：US12077600B2

公开(公告)日：2024-09-03

申请号：US17069349

申请日：2020-10-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Hartmut Duefel ,  Alfred Engel ,  Frank Kroner ,  Thomas Meier ,  Sandra Rutz ,  Michael Schraeml ,  Gloria Tabares ,  Ulrike Kurtkaya ,  Boris Pinchuk ,  Christina Zimmermann

IPC: G01N31/00 ,  C07K16/40 ,  G01N33/53 ,  G01N33/543

CPC classification number: C07K16/40 ,  G01N33/54326 ,  C07K2317/92

Abstract: The present invention relates to a novel monoclonal antibody that specifically binds to a conformation dependent epitope on human thymidine kinase 1 (hTK-1; SEQ ID NO:1), to methods for quantifying hTK-1 employing the antibody and to the use of the anti-hTK-1 antibody in quantifying hTK-1.

公开(公告)号：US20180231570A1

公开(公告)日：2018-08-16

申请号：US15943104

申请日：2018-04-02

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Andrea Horsch ,  Birgit Klapperich ,  Dirk Block ,  Alfred Engel ,  Johann Karl ,  Rosemarie Kientsch-Engel ,  Ekaterina Manuilova ,  Christina Rabe ,  Sandra Rutz ,  Monika Soukupova ,  Ursula-Henrike Wienhues-Thelen ,  Peter Kastner ,  Edelgard Anna Kaiser

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N33/68 ,  G01N33/74 ,  G01N2333/47 ,  G01N2333/8139 ,  G01N2800/347 ,  G01N2800/50

Abstract: The present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to the surgical procedure or prior to the administration of a contrast medium. Further, the present disclosure describes a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7 (Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present disclosure further encompasses kits and devices adapted to carry out the methods of the disclosed methods.

公开(公告)号：US20160102298A1

公开(公告)日：2016-04-14

申请号：US14970832

申请日：2015-12-16

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Tibor Czabany ,  Alfred Engel ,  Michael Greif ,  Christine Jung ,  Christiane Luley ,  Sebastian Malik ,  Rainer Mueller ,  Bernd Nidetzky ,  Doris Ribitsch ,  Katharina Schmoelzer ,  Helmut Schwab ,  Harald Sobek ,  Bernhard Suppmann ,  Marco Thomann ,  Sabine Zitzenbacher

IPC: C12N9/10

CPC classification number: C12N9/1081 ,  C12N9/1048 ,  C12Y204/99001

Abstract: The present disclosure is directed to glycosyltransferase variants having N-terminal truncation deletions. Contrary to previous findings certain truncations comprising the conserved amino acid motif (“QVWxKDS”) were found to be compatible with glycosyltransferase enzymatic activity, particularly in a human sialyltransferase (hST6Gal-I). Thus, disclosed are variants of mammalian glycosyltransferase, nucleic acids encoding the same, methods and means for recombinantly producing the variants of mammalian glycosyltransferase and use thereof, particularly for sialylating terminal acceptor groups of glycan moieties being part of glycoproteins such as immunoglobulins.

Abstract translation: 本公开涉及具有N-末端截短缺失的糖基转移酶变体。 与之前的发现相反，发现包含保守氨基酸基序（“QVWxKDS”）的某些截短与糖基转移酶酶活性相容，特别是在人唾液酸转移酶（hST6Gal-1）中。 因此，公开了哺乳动物糖基转移酶的变体，编码它们的核酸，用于重组产生哺乳动物糖基转移酶变体的方法和手段及其用途，特别是用作糖蛋白的部分的聚糖末端受体基团，例如免疫球蛋白。